198 related articles for article (PubMed ID: 20038315)
21. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
Inoue A; Yoshida K; Morita S; Imamura F; Seto T; Okamoto I; Nakagawa K; Yamamoto N; Muto S; Fukuoka M
Jpn J Clin Oncol; 2016 May; 46(5):462-7. PubMed ID: 26977054
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T
Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
[TBL] [Abstract][Full Text] [Related]
24. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
25. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
Ichihara E; Hotta K; Takigawa N; Kudo K; Kato Y; Honda Y; Hayakawa H; Minami D; Sato A; Tabata M; Tanimoto M; Kiura K
Lung Cancer; 2013 Sep; 81(3):435-439. PubMed ID: 23809059
[TBL] [Abstract][Full Text] [Related]
26. Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens.
Daniele L; Macrì L; Schena M; Dongiovanni D; Bonello L; Armando E; Ciuffreda L; Bertetto O; Bussolati G; Sapino A
Mol Cancer Ther; 2007 Apr; 6(4):1223-9. PubMed ID: 17406029
[TBL] [Abstract][Full Text] [Related]
27. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
Han SW; Kim TY; Jeon YK; Hwang PG; Im SA; Lee KH; Kim JH; Kim DW; Heo DS; Kim NK; Chung DH; Bang YJ
Clin Cancer Res; 2006 Apr; 12(8):2538-44. PubMed ID: 16638863
[TBL] [Abstract][Full Text] [Related]
28. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer.
Parra HS; Cavina R; Latteri F; Zucali PA; Campagnoli E; Morenghi E; Grimaldi GC; Roncalli M; Santoro A
Br J Cancer; 2004 Jul; 91(2):208-12. PubMed ID: 15187994
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma.
Toyooka S; Takano T; Kosaka T; Hotta K; Matsuo K; Ichihara S; Fujiwara Y; Soh J; Otani H; Kiura K; Aoe K; Yatabe Y; Ohe Y; Mitsudomi T; Date H
Cancer Sci; 2008 Feb; 99(2):303-8. PubMed ID: 18271929
[TBL] [Abstract][Full Text] [Related]
30. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
He C; Liu M; Zhou C; Zhang J; Ouyang M; Zhong N; Xu J
Int J Cancer; 2009 Nov; 125(10):2393-9. PubMed ID: 19530244
[TBL] [Abstract][Full Text] [Related]
31. Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer.
Wu JY; Yang CH; Hsu YC; Yu CJ; Chang SH; Shih JY; Yang PC
Clin Lung Cancer; 2010 Jul; 11(4):257-63. PubMed ID: 20630828
[TBL] [Abstract][Full Text] [Related]
32. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
Asahina H; Yamazaki K; Kinoshita I; Sukoh N; Harada M; Yokouchi H; Ishida T; Ogura S; Kojima T; Okamoto Y; Fujita Y; Dosaka-Akita H; Isobe H; Nishimura M
Br J Cancer; 2006 Oct; 95(8):998-1004. PubMed ID: 17047648
[TBL] [Abstract][Full Text] [Related]
33. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.
Zhou Q; Zhang XC; Chen ZH; Yin XL; Yang JJ; Xu CR; Yan HH; Chen HJ; Su J; Zhong WZ; Yang XN; An SJ; Wang BC; Huang YS; Wang Z; Wu YL
J Clin Oncol; 2011 Aug; 29(24):3316-21. PubMed ID: 21788562
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
[TBL] [Abstract][Full Text] [Related]
35. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
Cappuzzo F; Gregorc V; Rossi E; Cancellieri A; Magrini E; Paties CT; Ceresoli G; Lombardo L; Bartolini S; Calandri C; de Rosa M; Villa E; Crino L
J Clin Oncol; 2003 Jul; 21(14):2658-63. PubMed ID: 12860941
[TBL] [Abstract][Full Text] [Related]
36. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
Ebi N; Semba H; Tokunaga SJ; Takayama K; Wataya H; Kuraki T; Yamamoto H; Akamine SJ; Okamoto I; Nakanishi Y;
J Thorac Oncol; 2008 Oct; 3(10):1166-71. PubMed ID: 18827614
[TBL] [Abstract][Full Text] [Related]
37. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
[TBL] [Abstract][Full Text] [Related]
38. [Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].
Sun LN; Luan HL; Zang FL; Wang M; Dong N; Guo Y; Sun BC; Zhan ZL
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):667-70. PubMed ID: 21122380
[TBL] [Abstract][Full Text] [Related]
39. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
Yeo WL; Riely GJ; Yeap BY; Lau MW; Warner JL; Bodio K; Huberman MS; Kris MG; Tenen DG; Pao W; Kobayashi S; Costa DB
J Thorac Oncol; 2010 Jul; 5(7):1048-53. PubMed ID: 20512075
[TBL] [Abstract][Full Text] [Related]
40. The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.
Sun JM; Won YW; Kim ST; Kim JH; Choi YL; Lee J; Park YH; Ahn JS; Park K; Ahn MJ
J Cancer Res Clin Oncol; 2011 Apr; 137(4):687-94. PubMed ID: 20552223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
